J9033
J9033 – Injection, bendamustine hcl (treanda), 1 mg · NDC Crosswalk & Billing Units
HCPCS Level II J-code · Medicare Part B drug billing
J-code
● 11 NDCs crosswalked per 1 MG $2.960/unit ASP+6%
📋 J9033 summary
J9033 is a HCPCS Level II J-code used to bill bendamustine hcl (treanda), 1 mg, billed per 1 MG. The number of billing units to report depends on the dose administered and the NDC/package billed — use the calculator below.
Brand names associated with J9033: Bendamustine Hydrochloride, Treanda, Bendamustine
Code J9033
Billing unit 1 MG Payment limit $2.960/unit NDC-Crosswalk 11
Quarter Q3 2026
RxCUI Atlas Trace the drug concept →
⚠ An NDC↔HCPCS crosswalk and a published payment limit do not guarantee payer coverage or payment. Always verify the current payer policy and claim format before billing.
🗂️ Key billing facts
HCPCS codeJ9033
DescriptorInjection, bendamustine hcl (treanda), 1 mg
Billing unit1 MG
Payment limit / unit$2.960
Est. ASP / unit$2.792 est.
Mapped NDCs11
Data periodQ3 2026
Last updated2026-08-20
💊 About Bendamustine DRUG GUIDE
Bendamustine is used to treat adults with chronic lymphocytic leukemia (CLL).
It is also used to treat adults with indolent B-cell non-Hodgkin lymphoma (NHL) — specifically when that lymphoma has continued to grow during, or within six months of, treatment with rituximab or a rituximab-containing regimen.All available bendamustine products — including Belrapzo, Bendeka, Treanda, and Vivimusta — share these two indications.
Note that for CLL, how well bendamustine works compared to first-line treatments other than chlorambucil has not been fully established.
Clinical overview from our editorial drug guide for Bendamustine. For billing reference, see the sections above.
🧾 Billing & reimbursement HCPCS · CMS · EFF. Q3 2026
📅 Payment limits effective Q3 2026 — from the CMS Medicare Part B Payment Limit File (revised quarterly).
Medicare payment limit / unit
$2.960
Est. ASP / unit
$2.792 est.
Est. after 2% sequester
$2.901
HCPCS dosage
1 MG
The CMS payment limit is the Medicare Part B drug allowance (ASP + 6%, statutory). After the 2% federal sequester the effective payment is ≈ ASP + 4.3%; estimated ASP = payment limit ÷ 1.06. Source: CMS Medicare Part B Payment Limit File (quarterly), Q3 2026.
Full HCPCS code details (official CMS record)
Long descriptionInjection, bendamustine hcl (treanda), 1 mg
CoverageC — Carrier/MAC judgment
Pricing indicator51 — Drug — priced under the ASP methodology
Type of service1 — Medical care
BETOS-2O1D
ASC payment groupYY
Action codeN — No maintenance this year
Effective date2017-01-01
Date added2009-01-01
Source: CMS HCPCS Level II code file (imported via admin).
🧮 Dosing & billing-units calculator HCPCS UNITS
One billing unit of J9033 = 1 mg. Enter a regimen to convert dose → billing units and project a full course.
Billing units = dose ÷ HCPCS unit size. Most payers require whole units — round per the payer's policy. “Est. Medicare pay” uses the current payment limit. For single-dose vials, drug discarded after administration may be separately billable with modifier JW (JZ when none is discarded) where allowed. Always verify payer-specific rounding before billing.
🔁 NDCs that bill under J9033 WITH EST. MEDICARE PAY
11 NDCs map to J9033. Bill units = how many HCPCS units one package represents. Est. pay / pkg = payment limit ($2.960/unit) × that package's bill units.
| NDC (11-digit) | Drug | Labeler | Package | Strength | Bill units | Est. pay / pkg | NADAC / unit | Status | Source |
|---|---|---|---|---|---|---|---|---|---|
| 16729-0250-03 | bendamustine hydrochloride 25 mg/5mL INJECTION, POWDER, LYOPHILIZED, FOR SOLUTION | Accord | 1 VIAL, SINGLE-DOSE in 1 CARTON (16729-250... | 25 mg/5mL | 25 | $74.00 | — | ● Active | CMS ASP |
| 16729-0251-05 | bendamustine hydrochloride 100 mg/20mL INJECTION, POWDER, LYOPHILIZED, FOR SOLUTION | Accord | 1 VIAL, SINGLE-DOSE in 1 CARTON (16729-251... | 100 mg/20mL | 100 | $296.00 | — | ● Active | CMS + PDAC |
| 55150-0391-01 | BENDAMUSTINE HYDROCHLORIDE 25 mg/5mL INJECTION, POWDER, LYOPHILIZED, FOR SOLUTION | Eugia | 1 VIAL, SINGLE-DOSE in 1 CARTON (55150-391... | 25 mg/5mL | 25 | $74.00 | — | ● Active | CMS ASP |
| 55150-0392-01 | BENDAMUSTINE HYDROCHLORIDE 100 mg/20mL INJECTION, POWDER, LYOPHILIZED, FOR SOLUTION | Eugia | 1 VIAL, SINGLE-DOSE in 1 CARTON (55150-392... | 100 mg/20mL | 100 | $296.00 | — | ● Active | CMS + PDAC |
| 60505-6095-00 | Bendamustine Hydrochloride | Apotex | — | — | 25 | $74.00 | — | — | CMS ASP |
| 60505-6096-00 | Bendamustine | Apotex | — | — | 100 | $296.00 | — | — | CMS + PDAC |
| 63459-0390-08 | TREANDA Bendamustine Hydrochloride 25 mg/5mL INJECTION, POWDER, LYOPHILIZED, FOR SOLUTION | Cephalon, | 1 VIAL, SINGLE-DOSE in 1 CARTON (63459-390... | 25 mg/5mL | 25 | $74.00 | — | ● Active | CMS ASP |
| 63459-0391-20 | TREANDA Bendamustine Hydrochloride 100 mg/20mL INJECTION, POWDER, LYOPHILIZED, FOR SOLUTION | Cephalon, | 1 VIAL, SINGLE-DOSE in 1 CARTON (63459-391... | 100 mg/20mL | 100 | $296.00 | — | ● Active | CMS ASP |
| 68001-0572-41 | bendamustine hydrochloride 100 mg/20mL INJECTION, POWDER, LYOPHILIZED, FOR SOLUTION | BluePoint | 1 VIAL, SINGLE-DOSE in 1 CARTON (68001-572... | 100 mg/20mL | 100 | $296.00 | — | ● Active | CMS + PDAC |
| 71288-0102-10 | Bendamustine 25 mg/5mL INJECTION, POWDER, LYOPHILIZED, FOR SOLUTION | Meitheal | 1 VIAL, SINGLE-DOSE in 1 CARTON (71288-102... | 25 mg/5mL | 25 | $74.00 | — | ● Active | CMS ASP |
| 71288-0103-20 | Bendamustine 100 mg/20mL INJECTION, POWDER, LYOPHILIZED, FOR SOLUTION | Meitheal | 1 VIAL, SINGLE-DOSE in 1 CARTON (71288-103... | 100 mg/20mL | 100 | $296.00 | — | ● Active | CMS + PDAC |
NDC→HCPCS mappings come from the CMS ASP NDC-HCPCS crosswalk; additional DME MAC / DMEPOS mappings come from PDAC and are labeled separately. NADAC from CMS (weekly). “Status” reflects the product's marketing / obsolete flag in the NDC directory. Presence or absence here does not determine Medicare coverage. Linked NDCs open the full product page.
📊 Medicare utilization & spend CMS · PART B · 2026 (Q1)
Period
Total Part B spend
$211.3K
Claims
507
Beneficiaries
167
Spend / beneficiary
$1,265.48
Spend / claim
$416.83
Trend by period
Where J9033 ranks among Part B drugs · 2026 (Q1) · neighbors ±5
Total spending — #522 of 824
#517
XWRAP DUAL, PER SQ C... Q4358
$220.2K
#518
CYANOCOBALAMIN INJEC... J3420
$219.2K
#519
ALBUKED-25(P9046)* P9046
$215K
#520
PRIMATRIX** Q4110
$215K
#521
PEMETREXED DISODIUM(... J9294
$212.3K
#522
BENDAMUSTINE HCL* J9033
$211.3K
#523
HYCAMTIN J8705
$208.5K
#524
UZEDY J2799
$206.9K
#525
OXALIPLATIN J9263
$201.6K
#526
ORION, PER SQ CM** Q4276
$197.2K
#527
ARTACENT WOUND, PER... Q4169
$196.1K
Total claims — #452 of 824
#447
BUMETANIDE J1939
532
#448
LYUMJEV J1813
526
#449
LEVOFLOXACIN-D5W J1956
524
#450
RISPERDAL CONSTA* J2794
517
#451
ALBUMIN (HUMAN)* P9041
514
#452
BENDAMUSTINE HCL* J9033
507
#453
CEREZYME J1786
506
#454
IMLYGIC J9325
503
#455
MICAFUNGIN(J2248)* J2248
497
#456
ADSTILADRIN J9029
497
#457
XCELL AMNIO MATRIX P... Q4280
495
Top Medicare Part B drugs by the selected metric. Click any drug to open its J-code page. Source: CMS Medicare Quarterly Part B Spending by Drug.
Full breakdown by period (2)
| Period | Total spend | Beneficiaries | Claims | $/beneficiary | $/claim |
|---|---|---|---|---|---|
| 2026 (Q1) | $211.3K | 167 | 507 | $1,265.48 | $416.83 |
| 2025 (Q1-Q4) | $919.9K | 576 | 2,791 | $1,597.03 | $329.59 |
Provider-administered (Part B) spend, calculated for the whole HCPCS code (CMS does not publish Medicare spend per individual NDC). Self-administered use is covered under Part D instead. A blank patient count means fewer than 11 people — CMS hides counts that small to protect privacy. Source: CMS Medicare Quarterly Part B Spending by Drug (data.cms.gov), updated quarterly.
📈 Medicare Part B claims detail CMS PSPS · 2024
Calendar-year 2024 Medicare Part B fee-for-service activity for this HCPCS code, summed across all carriers, localities and specialties (CMS Physician/Supplier Procedure Summary). A “service” is one billed line/unit — not one claim — so counts run higher than claim counts.
Allowed charges
$321.8K
Medicare paid
$243.1K
Submitted services
205,043
Denial rate
7.1%
Allowed / service
$1.69
Submitted charges
$8.31M
Source: CMS Physician/Supplier Procedure Summary (PSPS), CY2024 — Medicare Part B carrier + DME fee-for-service claims (excludes Medicare Advantage). Figures are for the whole HCPCS code, which may cover uses beyond this drug. ⚠ CMS hides any figure covering fewer than 11 patients (a privacy rule), so totals — especially denials and low-volume codes — run a little low.
🗺️ Where J9033 is utilized
⏳
The geographic utilization map is building for this code — it aggregates millions of CMS Part B claim lines, then caches the result. Refresh in a moment; if it doesn’t appear, this code may have no reportable Part B utilization.
📊 What bills under J9033
J-codes are billing codes often used for drugs billed under the medical benefit. This connects the billing code to the NDC package records it covers, by ingredient and labeler.
NDC products by ingredient
NDC products by labeler
🗃️ Data sources & freshness
Every figure on this page is computed from public datasets. Here's what each section draws on and how current it is.
HCPCS code & descriptor
CMS HCPCS Level II code file
Loaded
Payment limit & billing unit
CMS Medicare Part B ASP Pricing File (quarterly)
Q3 2026 · as of 2026-08-20
NDC ↔ HCPCS crosswalk
CMS ASP NDC-HCPCS crosswalk + DMEPDAC (PDAC)
11 NDCs mapped
NADAC acquisition cost
CMS National Average Drug Acquisition Cost (weekly)
Not available for mapped NDCs
Utilization & spend
CMS Part B Spending by Drug · PSPS · Physician & Other Practitioners
Latest data year 2026
Figures are estimates for reference and may lag the source files. Always verify against the current CMS files and your payer's policy before submitting claims.
⚠️ Practical billing caveats
- A crosswalk is not coverage. An NDC mapping or a published payment limit does not guarantee a payer will cover or pay this code. Check the specific plan's policy.
- Units ≠ milligrams. Bill the number of HCPCS units (dose ÷ the code's unit size), not the milligram dose. Use the calculator above.
- Discarded drug. For single-dose vials, drug discarded after administration may be separately billable with modifier JW (and JZ when nothing is discarded) where the payer allows.
- Rounding & partial units. Many payers require whole units; round per the payer's policy, not automatically up.
- The code can cover more than this drug. Some HCPCS codes span multiple products or strengths — confirm the exact code for the product administered.
- Figures lag. ASP limits change quarterly and utilization data are released with a delay. Verify against the current CMS files before billing.
❓ J9033 billing FAQ
What is HCPCS code J9033?
J9033 is a HCPCS Level II J-code used to bill Injection, bendamustine hcl (treanda), 1 mg under Medicare Part B and most medical (not pharmacy) benefits.
What is the billing unit for J9033?
One unit of J9033 represents 1 MG. Report the number of units equal to the dose administered divided by 1 MG.
How many units of J9033 should I bill?
Divide the dose administered by the code's unit size (1 MG) to get the number of billing units, then round per your payer's policy. The calculator on this page converts a dose into billing units and projects a full course.
How much does Medicare pay for J9033?
The Medicare Part B payment limit is $2.960 per unit (Q3 2026), based on ASP + 6%. After the 2% sequester the effective payment is about $2.901 per unit. Payment limits are revised quarterly.
Which NDCs bill under J9033?
11 NDCs currently map to J9033 in the CMS ASP NDC-HCPCS crosswalk. See the NDC crosswalk table above for each product, package, billing units and estimated reimbursement.
Does a crosswalk mean J9033 is covered?
No. An NDC-to-HCPCS crosswalk and a published payment limit do not guarantee coverage or payment. Coverage depends on the payer, the diagnosis and the site of care — always verify the current policy before billing.
For professional billing reference only — verify against the current CMS files before submitting claims.